Sound Shore Management Inc. CT Acquires 201,445 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Sound Shore Management Inc. CT boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 23.7% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,052,202 shares of the medical equipment provider’s stock after buying an additional 201,445 shares during the quarter. Zimmer Biomet accounts for about 3.2% of Sound Shore Management Inc. CT’s investment portfolio, making the stock its 6th largest position. Sound Shore Management Inc. CT’s holdings in Zimmer Biomet were worth $95,140,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Parallel Advisors LLC boosted its stake in shares of Zimmer Biomet by 32.1% during the 1st quarter. Parallel Advisors LLC now owns 798 shares of the medical equipment provider’s stock worth $72,000 after acquiring an additional 194 shares in the last quarter. SEB Asset Management AB acquired a new stake in shares of Zimmer Biomet during the first quarter worth $3,574,000. Swiss National Bank raised its position in shares of Zimmer Biomet by 7.1% during the first quarter. Swiss National Bank now owns 581,700 shares of the medical equipment provider’s stock worth $52,597,000 after purchasing an additional 38,800 shares during the period. Annis Gardner Whiting Capital Advisors LLC lifted its holdings in shares of Zimmer Biomet by 39.0% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 1,807 shares of the medical equipment provider’s stock valued at $163,000 after purchasing an additional 507 shares during the last quarter. Finally, Kera Capital Partners Inc. purchased a new stake in shares of Zimmer Biomet during the first quarter valued at $227,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ZBH shares. Truist Financial reissued a “hold” rating and issued a $92.00 price target (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Wells Fargo & Company reduced their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 29th. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. BTIG Research reiterated a “neutral” rating on shares of Zimmer Biomet in a report on Monday, March 23rd. Finally, JPMorgan Chase & Co. dropped their target price on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $100.70.

Zimmer Biomet Stock Up 0.1%

ZBH stock opened at $91.18 on Monday. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $108.29. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50. The company has a market cap of $17.64 billion, a price-to-earnings ratio of 23.68, a PEG ratio of 2.68 and a beta of 0.46. The company has a 50 day moving average of $87.17 and a two-hundred day moving average of $89.82.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, beating the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. The business had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same period in the previous year, the company posted $1.81 EPS. Zimmer Biomet’s revenue was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s payout ratio is 24.94%.

Insider Buying and Selling

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.28% of the stock is owned by company insiders.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.